Forkhead box A1 (FOXA1) is a key mediator of insulin-like growth factor i (IGF-I) activity

Journal of Cellular Biochemistry

Volumn 113, Issue 1, 2012, Pages 110-121

  Potter, Adam S ^a   Casa, Angelo J ^a   Lee, Adrian V ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Breast cancer; FOXA1; Gene regulation; IGF I

Indexed keywords

HEPATOCYTE NUCLEAR FACTOR 3ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SOMATOMEDIN C;

APOPTOSIS; ARTICLE; BINDING SITE; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; SIGNAL TRANSDUCTION;

APOPTOSIS; BINDING SITES; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASE; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84055177114     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.23333     Document Type: Article

References (39)

1. Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H,. 2007. FOXA1 expression in breast cancer-correlation with luminal subtype A and survival. Clin Cancer Res 13: 4415-4421. (Pubitemid 47219708)
2. Becker MA, Ibrahim YH, Cui X, Lee AV, Yee D,. 2011. The IGF pathway regulates ERalpha through a S6K1-dependent mechanism in breast cancer cells. Mol Endocrinol 25: 516-528.
3. Bernardo GM, Lozada KL, Miedler JD, Harburg G, Hewitt SC, Mosley JD, Godwin AK, Korach KS, Visvader JE, Kaestner KH, Abdul-Karim FW, Montano MM, Keri RA,. 2010. FOXA1 is an essential determinant of ERalpha expression and mammary ductal morphogenesis. Development 137: 2045-2054.
4. Blank V,. 2008. Small Maf proteins in mammalian gene control: Mere dimerization partners or dynamic transcriptional regulators? J Mol Biol 376: 913-925.
5. Bonnette SG, Hadsell DL,. 2001. Targeted disruption of the IGF-I receptor gene decreases cellular proliferation in mammary terminal end buds. Endocrinology 142: 4937-4945. (Pubitemid 33022370)
6. Carboni JM, Lee AV, Hadsell DL, Rowley BR, Lee FY, Bol DK, Camuso AE, Gottardis M, Greer AF, Ho CP, Hurlburt W, Li A, Saulnier M, Velaparthi U, Wang C, Wen ML, Westhouse RA, Wittman M, Zimmermann K, Rupnow BA, Wong TW,. 2005. Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res 65: 3781-3787. (Pubitemid 40616356)
7. Carroll JS, Liu XS, Brodsky AS, Li W, Meyer CA, Szary AJ, Eeckhoute J, Shao W, Hestermann EV, Geistlinger TR, Fox EA, Silver PA, Brown M,. 2005. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 122: 33-43. (Pubitemid 40977938)
8. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, Brodsky AS, Keeton EK, Fertuck KC, Hall GF, Wang Q, Bekiranov S, Sementchenko V, Fox EA, Silver PA, Gingeras TR, Liu XS, Brown M,. 2006. Genome-wide analysis of estrogen receptor binding sites. Nat Genet 38: 1289-1297. (Pubitemid 44646291)
9. Chitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM,. 2008. The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res 14: 6364-6370.
10. Cirillo LA, Lin FR, Cuesta I, Friedman D, Jarnik M, Zaret KS,. 2002. Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4. Mol Cell 9: 279-289. (Pubitemid 34195554)
11. Creighton CJ, Casa A, Lazard Z, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Lee AV,. 2008. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol 26: 4078-4085.
12. Dearth RK, Cui X, Kim HJ, Hadsell DL, Lee AV,. 2007. Oncogenic transformation by the signaling adaptor proteins insulin receptor substrate (IRS)-1 and IRS-2. Cell Cycle 6: 705-713. (Pubitemid 46535683)
13. Duncan SA, Navas MA, Dufort D, Rossant J, Stoffel M,. 1998. Regulation of a transcription factor network required for differentiation and metabolism. Science 281: 692-695. (Pubitemid 28387279)
14. Flemming A, Brummer T, Reth M, Jumaa H,. 2003. The adaptor protein SLP-65 acts as a tumor suppressor that limits pre-B cell expansion. Nat Immunol 4: 38-43. (Pubitemid 36104706)
15. Haffner MC, Petridou B, Peyrat JP, Revillion F, Muller-Holzner E, Daxenbichler G, Marth C, Doppler W,. 2007. Favorable prognostic value of SOCS2 and IGF-I in breast cancer. BMC Cancer 7: 136.
16. Howell JJ, Stoffel M,. 2009. Nuclear export-independent inhibition of Foxa2 by insulin. J Biol Chem 284: 24816-24824.
17. Jag UR, Zavadil J, Stanley FM,. 2009. Insulin acts through FOXO3a to activate transcription of plasminogen activator inhibitor type 1. Mol Endocrinol 23: 1587-1602.
18. Jones RA, Campbell CI, Gunther EJ, Chodosh LA, Petrik JJ, Khokha R, Moorehead RA,. 2007. Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation. Oncogene 26: 1636-1644. (Pubitemid 46398739)
19. Kohler S, Cirillo LA,. 2010. Stable chromatin binding prevents FoxA acetylation, preserving FoxA chromatin remodeling. J Biol Chem 285: 464-472.
20. Laganiere J, Deblois G, Lefebvre C, Bataille AR, Robert F, Giguere V,. 2005. From the cover: Location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response. Proc Natl Acad Sci USA 102: 11651-11656. (Pubitemid 41170781)
21. Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, Park E, Gee JM, Finlay P, Jones HE, Nicholson RI, Carboni J, Gottardis M, Pollak M, Dunn SE,. 2008. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 68: 10238-10246.
22. LeRoith D, Roberts CT, Jr., 2003. The insulin-like growth factor system and cancer. Cancer Lett 195: 127-137. (Pubitemid 36588961)
23. Livak KJ, Schmittgen TD,. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408. (Pubitemid 34164012)
24. Maor S, Mayer D, Yarden RI, Lee AV, Sarfstein R, Werner H, Papa MZ,. 2006. Estrogen receptor regulates insulin-like growth factor-I receptor gene expression in breast tumor cells: Involvement of transcription factor Sp1. J Endocrinol 191: 605-612. (Pubitemid 46210286)
25. Martin BT, Kleiber K, Wixler V, Raab M, Zimmer B, Kaufmann M, Strebhardt K,. 2007. FHL2 regulates cell cycle-dependent and doxorubicin-induced p21Cip1/Waf1 expression in breast cancer cells. Cell Cycle 6: 1779-1788. (Pubitemid 47327932)
26. Matsuzaki H, Daitoku H, Hatta M, Tanaka K, Fukamizu A,. 2003. Insulin-induced phosphorylation of FKHR (Foxo1) targets to proteasomal degradation. Proc Natl Acad Sci USA 100: 11285-11290. (Pubitemid 37205927)
27. Ogg S, Paradis S, Gottlieb S, Patterson GI, Lee L, Tissenbaum HA, Ruvkun G,. 1997. The Fork head transcription factor DAF-16 transduces insulin-like metabolic and longevity signals in C. elegans. Nature 389: 994-999. (Pubitemid 27485694)
28. Pollak M,. 2008. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8: 915-928.
29. Schuur ER, Loktev AV, Sharma M, Sun Z, Roth RA, Weigel RJ,. 2001. Ligand-dependent interaction of estrogen receptor-alpha with members of the forkhead transcription factor family. J Biol Chem 276: 33554-33560.
30. Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A, Baserga R,. 1993. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci USA 90: 11217-11221. (Pubitemid 23354400)
31. Sircoulomb F, Bekhouche I, Finetti P, Adelaide J, Ben H, Bonansea A, Raynaud J, Innocenti S, Charafe-Jauffret C, Tarpin E, Ben C, Ayed F, Viens P, Jacquemier J, Bertucci F, Birnbaum D, Chaffanet M,. 2010. Genome profiling of ERBB2-amplified breast cancers. BMC Cancer 10: 539.
32. Stratikopoulos E, Szabolcs M, Dragatsis I, Klinakis A, Efstratiadis A,. 2008. The hormonal action of IGF1 in postnatal mouse growth. Proc Natl Acad Sci USA 105: 19378-19383.
33. Surmacz E,. 2000. Function of the IGF-I receptor in breast cancer. J Mammary Gland Biol Neoplasia 5: 95-105.
34. Werner H, Bruchim I,. 2009. The insulin-like growth factor-I receptor as an oncogene. Arch Physiol Biochem 115: 58-71.
35. Weroha SJ, Haluska P,. 2008. IGF-1 receptor inhibitors in clinical trials-early lessons. J Mammary Gland Biol Neoplasia 13: 471-483.
36. Wilk A, Urbanska K, Yang S, Wang JY, Amini S, Del Valle L, Peruzzi F, Meggs L, Reiss K,. 2011. Insulin-like growth factor-I-forkhead box O transcription factor 3a counteracts high glucose/tumor necrosis factor-alpha-mediated neuronal damage: Implications for human immunodeficiency virus encephalitis. J Neurosci Res 89: 183-198.
37. Wolfrum C, Besser D, Luca E, Stoffel M,. 2003. Insulin regulates the activity of forkhead transcription factor Hnf-3beta/Foxa-2 by Akt-mediated phosphorylation and nuclear/cytosolic localization. Proc Natl Acad Sci USA 100: 11624-11629. (Pubitemid 37205986)
38. Zapf J, Schmid C, Froesch ER,. 1984. Biological and immunological properties of insulin-like growth factors (IGF) I and II. Clin Endocrinol Metab 13: 3-30. (Pubitemid 14141808)
39. Zheng WH, Kar S, Quirion R,. 2000. Insulin-like growth factor-1-induced phosphorylation of the forkhead family transcription factor FKHRL1 is mediated by Akt kinase in PC12 cells. J Biol Chem 275: 39152-39158. (Pubitemid 32058931)